| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 22, 2018Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.
22 Jun 2018 KING OF PRUSSIA, Pa. – June 22, 2018 – An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring’s 2018 Prof. Heimburger Award...
-
Jun 15, 2018- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients - CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress
15 Jun 2018 LISBON, Portugal – 15 June 2018 – Global biotherapeutics leader CSL Behring today announced that it will participate in the 4th Congress of the European Academy of Neurology (EAN)...
-
May 31, 2018• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions • New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
31 May 2018 KING OF PRUSSIA, Pa. – 31 May 2018 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international...
-
May 14, 2018HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance
14 May 2018 East Brunswick, N.J. – May 14, 2018 – CEO and Managing Director of CSL Limited Paul Perreault has been named “Humanitarian Man of the Year” by the Hemophilia Association of New...
-
Apr 26, 2018Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018
26 Apr 2018 KING OF PRUSSIA, Pa. – April 26, 2018 – Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing...
-
Apr 20, 2018- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM
- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms - CSL Behring is now the only company to offer a portfolio of...
-
Apr 12, 2018CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
12 Apr 2018 MONTREAL and KING OF PRUSSIA, Pa. – April 12, 2018 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has...
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Mar 20, 2018Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
20 Mar 2018 KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s...
-
Mar 16, 2018First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018 KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune...